Society of Hematologic Oncology Annual Meeting (SOHO) | Conference

Therapeutic Challenge Exists With Treating Accelerated Phase Myeloproliferative Neoplasms
October 16, 2021

There remains a therapeutic challenge with understanding and treating patients with accelerated myeloproliferative neoplasms.

New Targets Open Possibilities for Novel Antibodies and Cellular Therapies in CLL
October 01, 2021

As more novel therapeutic targets are discovered in patients with chronic lymphocytic leukemia, the more possibilities are presented in terms of treatment with targeted agents, small molecules, and cellular therapies.

Lower Survival Probability Observed for High-Risk Polycythemia Vera Compared With Low-Risk Disease
September 24, 2021

Patients with high-risk polycythemia vera had a worse survival probability at 4 years compared to patients with low-risk disease.

Adaptive Therapies and Novel Targets Will Play a Notable Role in the Future Treatment of Polycythemia Vera, Expert Says
September 15, 2021

Francesco Passamonti, MD, discusses the future of treatment for patients with polycythemia vera such as adaptive therapies and the utilization of novel targets.

Pirtobrutinib Yields Promising Responses in Previously Treated CLL/SLL
September 13, 2021

Patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma appeared to benefit from treatment with pirtobrutinib.

Pirtobrutinib Demonstrates Strong Response Rates for Previously Treated CLL/SLL
September 11, 2021

Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.

Despite Improved Survival Rates in T-ALL, Investigators Seek Further Improvements Through Immunotherapeutics
September 09, 2021

The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.